Daniel Lee Flynn - 16 Feb 2022 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc.

Role
Chief Scientific Officer
Signature
/s/ Jeffrey M. Held, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
16 Feb 2022
Net transactions value
-$12,362
Form type
4
Filing time
18 Feb 2022, 16:01:35 UTC
Previous filing
20 Jan 2022
Next filing
21 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DCPH Common Stock Sale $12,362 -1,366 -2.8% $9.05 47,866 16 Feb 2022 Direct F1
holding DCPH Common Stock 230,435 16 Feb 2022 By Daniel L. Flynn Revocable Trust
holding DCPH Common Stock 91,020 16 Feb 2022 By Daniel L. Flynn Irrevocable Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was to cover tax liabilities in the vesting of restricted stock.